Biomarkers · Chemical
A plain-language description with its source has not been added for this biomarker yet. What the laboratories say about the tests that measure it is below.
What the laboratory says this test is for
This reflex provides a cost-effective, medically justified, and guideline supported approach to evaluating a patient at risk of NAFLD with liver fibrosis. If the FIB-4 index is ≥1.30, the ELF score is performed.
Quest Diagnostics test directory, test code 12736
What the laboratory says this test is for
This reflex provides a cost-effective, medically justified, and guideline supported approach to evaluating a patient at risk of NAFLD with liver fibrosis. If the FIB-4 index is ≥1.30, the ELF score is performed.
Quest Diagnostics test directory, test code 12734
What the laboratory says this test is for
The FIB-4 index is a simple non-invasive approach using selected laboratory measures (AST, ALT, platelet count) in combination with patient age to assess if an individual is at higher risk for advanced liver fibrosis (F3-F4).
Quest Diagnostics test directory, test code 30555
What the laboratory says this test is for
The FIB-4 index is a simple non-invasive approach using selected laboratory measures (AST, ALT, platelet count) in combination with patient age to assess if an individual is at higher risk for advanced liver fibrosis (F3-F4).
Quest Diagnostics test directory, test code 10372
What the laboratory says this test is for
The NAFLD fibrosis score is a simple noninvasive approach to identify patients that may have significant liver fibrosis and who therefore might benefit from additional studies such as elastography or liver biopsy. Non-alcoholic fatty liver disease (NAFLD) affects approximately 30% of adults in developed countries. It is associated with obesity, diabetes, and dyslipidemia and is considered the liver manifestation of the metabolic syndrome. This disease is often asymptomatic. In some individuals, NAFLD is associated with inflammation (non-alcoholic steatohepatitis [NASH]) and may progress to liver fibrosis and ultimately to cirrhosis and attendant complications. Such individuals are also at risk for the development of hepatocellular carcinoma. In patients with NAFLD, liver fibrosis is an important prognostic factor that predicts progression and outcome. The NAFLD fibrosis score was initially published by Angulo et al. (Hepatology 45, 846 (2007)) and has since been extensively validated. The score assesses selected laboratory measures (glucose levels, platelet count, albumin, AST/ALT ratio) in combination with basic patient characteristics (age and BMI). The panel components and the NAFLD fibrosis score are recommended by professional societies including AASLD, AGA and ACG.
Quest Diagnostics test directory, test code 91979
What the laboratory says this test is for
The FIB-4 index is a simple non-invasive approach using selected laboratory measures (AST, ALT, platelet count) in combination with patient age to assess if an individual is at higher risk for advanced liver fibrosis (F3-F4).
Quest Diagnostics test directory, test code 30710
What the laboratory says this test is for
This panel combines tests used in the diagnosis and management of cardiometabolic disease elements, including metabolic syndrome, prediabetes, diabetes, thyroid conditions, kidney, fatty liver, and cardiovascular disease risk. This panel can help identify the presence and progression of cardiometabolic disease by assessing metabolic state and downstream effects on the liver, kidneys, and heart.It is estimated that as many as 45% of Americans have a chronic disease; more than half of older adults have multiple chronic conditions [1]. The related chronic cardiometabolic conditions are characterized by initial stages that may remain clinically silent for years.Medical societies, like the American Heart Association, recognize the interrelated impacts of metabolic risk factors (ie, obesity and diabetes), chronic kidney disease, and cardiovascular disease, and the gap in early screening, prevention, and management of these chronic conditions [2,3]. Rising rates of metabolic dysfunction, obesity, and type 2 diabetes mellitus (T2DM) also contribute to increased prevalence of nonalcoholic fatty liver disease (NAFLD), also known as metabolic dysfunction-associated steatotic liver disease (MASLD) [4]. Thyroid health may either be impacted by or exacerbate cardiometabolic conditions, such as CHD, NAFLD, and CKD [5-8].The Cardiometabolic Disease Assessment Panel includes guideline-recommended testing that spans interrelated areas of cardiometabolic disease to determine the extent of metabolic dysfunction (glycemic control and advanced lipid assessment), identify whether thyroid health contributes to or is altered by metabolic dysfunction, and adverse impacts to heart, liver, and kidney function [9-13]. Identification of cardiometabolic disease presence can help implement personalized treatment strategies that can prevent or delay disease progression and related complications.The results of this test should be interpreted in the context of pertinent clinical and family history and physical examination findings.References1. Raghupathi W, et al. Int J Environ Res Public Health. 2018;15(3):431. doi:10.3390/ijerph150304312. Ndumele CE, et al. Circulation. 2023;148(20):1636-1664. doi.org/10.1161/CIR.00000000000011863. Khan SS, et al. Circulation. 2024;149(6):430-449. doi: 10.1161/CIRCULATIONAHA.123.0676264. Bril F, et al. J Clin Endocrinol Metab. 2021;106(11):e4360-e4371. doi:10.1210/clinem/dgab4175. Cappola AR, et al. Circulation. 2019;139(25):2892- 2909. doi.org/10.1161/circulationaha.118.0368596. Kalra S, et al. Diabetes Ther. 2019;10(6):2035-2044. doi:10.1007/s13300-019-00700-47. Mantovani A, et al. Thyroid. 2018;28(10):1270-1284. doi:10.1089/ thy.2018.02578. Iglesias P, et al. Rev Endocr Metab Disord. 2017;18(1):131-144. doi:10.1007/s11154-016-9395-79. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2020. Diabetes Care. 2020;43(Suppl 1):S14-S31. doi: 10.2337/dc23-S00210 Arnett DK, et al. J Am Coll Cardiol. 2019. doi: 10.1161/CIR.000000000000067711. Cusi K, et al. Clinical Practice Guidelines. 2022;28(5):P528-562. doi:10.1016/j.eprac.2022.03.01012. Rinella NE, et al. Hepatology. 2023;77(5):1797-1835. doi:10.1097/HEP.000000000000032313. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. Kidney Int. 2024;105(4S):S117-S314. doi:10.1016/j.kint.2023.10.018
Quest Diagnostics test directory, test code 14273
What the laboratory says this test is for
This reflex provides a cost-effective, medically justified, and guideline supported approach to evaluating a patient at risk of NAFLD with liver fibrosis. If the FIB-4 index is ≥1.30, the ELF score is performed.
Quest Diagnostics test directory, test code 12735
What the laboratory says this test is for
A complete blood count is used as a screening test for various disease states to include: anemia, leukemia and inflammatory processes.
Quest Diagnostics test directory, test code 1759
What the laboratory says this test is for
A complete blood count is used as a screening test for various disease states to include: anemia, leukemia and inflammatory processes.
Quest Diagnostics test directory, test code 6399
Everything above is drawn from the named sources and shown as they published it. Reference ranges belong to the laboratory that issued them and the population it named; they are not a universal normal. This page describes the biomarker in general and does not interpret anyone's result. For your own numbers, talk to a clinician, or use Aumnivida, which reads the same graph next to your records.
Found an error? Write to hello@biomarkerlens.com with the page link and the source that contradicts it.